How to increase the density of NMDA receptors? upregulate NMDA? I know one method, namely the use of piracetam, but this makes me irritable, plus longer use despite addition of choline causes chronic fatigue ...
Other ways to upregulate NMDA?
Posted 25 December 2012 - 11:49 AM
Posted 25 December 2012 - 05:22 PM
Posted 25 December 2012 - 06:47 PM
Edited by scibor, 25 December 2012 - 06:47 PM.
Posted 25 December 2012 - 07:29 PM
Posted 26 December 2012 - 08:13 AM
Posted 28 December 2012 - 03:00 PM
Posted 14 February 2015 - 06:35 PM
This is the information you are looking for....OP --> http://area1255.blog...eptors-and.html
Edited by Area-1255, 14 February 2015 - 06:36 PM.
Posted 14 February 2015 - 09:47 PM
Though certainly weak, perhaps totally ineffective, magnesium is a safe option. You could get 200mg extra daily with just a few changes of diet.
Posted 14 February 2015 - 11:08 PM
Edited by Arjuna, 14 February 2015 - 11:09 PM.
Posted 15 February 2015 - 06:00 PM
Are there any prescription medications that would help or regulate the NMDA issues some people have?
For example,
R̲i̲l̲u̲z̲o̲l̲e̲, M̲e̲m̲a̲n̲t̲i̲n̲e̲, A̲m̲a̲n̲t̲a̲d̲i̲n̲e̲, or L̲a̲m̲o̲t̲r̲i̲g̲i̲n̲e̲?
I appologize if my understanding is not correct, I am still in the process of learning about these areas. Thanks for any help, corrections, and insight.
Posted 15 February 2015 - 08:23 PM
Are there any prescription medications that would help or regulate the NMDA issues some people have?
For example,
R̲i̲l̲u̲z̲o̲l̲e̲, M̲e̲m̲a̲n̲t̲i̲n̲e̲, A̲m̲a̲n̲t̲a̲d̲i̲n̲e̲, or L̲a̲m̲o̲t̲r̲i̲g̲i̲n̲e̲?
I appologize if my understanding is not correct, I am still in the process of learning about these areas. Thanks for any help, corrections, and insight.
Yes, NEFIRACETAM.
Though it's not a prescription medication, its a nootropic/research chemical.
Mol Pharmacol. 2007 Feb;71(2):580-7. Epub 2006 Nov 9.
Nefiracetam potentiates N-methyl-D-aspartate (NMDA) receptor function via protein kinase C activation and reduces magnesium block of NMDA receptor.AbstractNicotinic acetylcholine receptors and N-methyl-D-aspartate (NMDA) receptors are known to be down-regulated in the brain of Alzheimer's disease patients. We have previously demonstrated that the nootropic drug nefiracetam potentiates the activity of both nicotinic acetylcholine and NMDA receptors and that nefiracetam modulates the glycine binding site of the NMDA receptor. Because the NMDA receptor is also modulated by Mg2+ and protein kinases, we studied their roles in nefiracetam action on the NMDA receptor by the whole-cell patch-clamp technique and immunoblotting analysis using rat cortical or hippocampal neurons in primary culture. The nefiracetam potentiation of NMDA currents was inhibited by the protein kinase C (PKC) inhibitor chelerythrine, but not by the protein kinase A (PKA) inhibitor N-[2-(4-bromocinnamylamino)ethyl]-5-isoquinoline (H89). In immunoblotting analysis, nefiracetam treatment increased the PKCalpha activity with a bell-shaped dose-response relationship peaking at 10 nM, thereby increasing phosphorylation of PKC substrate and NMDA receptor. Such an increase in PKCalpha-mediated phosphorylation was prevented by chelerythine. Nefiracetam treatment did not affect the PKA activity. Analysis of the current-voltage relationships revealed that nefiracetam at 10 nM largely eliminated voltage-dependent Mg2+ block and that this action of nefiracetam was sensitive to PKC inhibition. It was concluded that nefiracetam potentiated NMDA currents not by acting as a partial agonist but by interacting with PKC, allosterically enhancing glycine binding, and attenuating voltage-dependent Mg2+ block.
PMID: 17095583 [PubMed - indexed for MEDLINE]
Edited by Area-1255, 15 February 2015 - 08:26 PM.
0 members, 12 guests, 0 anonymous users